Abstracts > Submission > Submission Guidelines
- Describe the objectives and results of the research in the abstract so that the ASCO Scientific Program Committee can evaluate the quality, originality, and completeness of the abstract. Abstracts will be judged solely on the basis of the data in the submitted abstract. Statements such as “further data will be available” are discouraged. Additional appendices, illustrations, or other supplementary materials will not be accepted. Submission of one data table is permitted.
- Organize the abstract according to four sections, identified by the following headers: Background, Methods, Results, and Conclusions.
- Adhere to the biostatistical guidelines set forth by the Biostatistics Core of the Scientific Program Committee. Although all of the elements are not required, the absence of one or more of these elements in an abstract may have a negative impact on the abstract review and placement process.
- Using the box on the Abstract Submitter, indicate whether patients are still being accrued to the study being reported. As a general rule, ASCO discourages submission of abstracts that report interim data from studies that are continuing to accrue patients (examples include phase I studies where recommended phase II dose is not yet determined, or phase II studies that are not fully enrolled). Acceptance of such abstracts will be considered on a case-by-case basis.
- Do not refer to study results or conclusions in the title of the abstract. The title should objectively describe the study. ASCO reserves the right to edit conclusive titles.
- Do not use proprietary names alone in the title or body of the abstract. If necessary, you may include a proprietary name in parentheses directly after the generic name on first use in the body of the abstract. ASCO reserves the right to replace proprietary names with generic names.
- Do not include illustrations with the abstract. You may include a data table created using the Abstract Submitter. Instructions for including a table with your abstract are provided on the Abstract Submission website.
- Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract. Take particular care to identify complex chemotherapy regimens accurately.
- Do not exceed 2,000 characters (approximately 300 to 350 words) for the total of your abstract title, body, and table. The character count does NOT include spaces or author names or institutions.
- List no more than 20 individual authors for each abstract. In addition to the 20 authors, an authoring group may also be used. Make sure that all coauthors meet the definition of authorship as stated by the International Committee of Medical Journal Editors in the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals."
- Include all coauthors and disclosure information for each coauthor by the February 2 deadline. Coauthor disclosure forms are available here.
- Though clinical trial registration is not required for abstract submission, publication, or presentation, certain clinical trials are required to be registered by law and/or prior to journal publication. If a clinical trial is already registered, the First Author will be asked to provide the name of the registry and the trial registration number during the abstract submission process.